|
|
3005 First Avenue
Seattle, WA 98121 USA
phone:(206) 256-4545
fax:(206) 256-0571
|
|
| Symbol |
DNDN |
| Exchange |
NASDAQ |
| Founded |
1992 |
| Employees |
117 |
|
|
| www.dendreon.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response to cancer |
|
| Management |
| Mitchell H. Gold, M.D., President and Chief Executive Officer and Director; Hans E. Bishop, Executive Vice President and Chief Operating Officer; Mark W. Frohlich, M.D., Senior Vice President, Clinical Affairs and Chief Medical Officer; Richard F. Hamm, Jr., Senior Vice President, Corporate Development, General Counsel, and Secretary; Gregory T. Schiffman, Senior Vice President and Chief Financial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| immunotherapy, metastatic, sipuleucel-t, carcinoembryonic, hormone-refractory, immunotherapy, cellular immunity, breast, ovarian, colon, lung |
|
|
|
| Description |
|
Dendreon Corporation (NASDAQ: DNDN), a Seattle-based biotechnology company, is focused on targeting cancer to transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. In addition to ACI product candidates, the company is also developing an orally-available small molecule targeting TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. |
|
| Products / Services |
PROVENGE? (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer.
|
|
|
| Competitors / Substitutes / Alternatives |
Biomira Inc (BIOM), Cell Genesys Inc (CEGE)
|
|
| Strategy |
Key elements of their business strategy include: maximizing speed to market of lead therapeutic vaccines, building a large and diverse product portfolio, retaining core commercialization rights, developing key collaborative agreements and effectively leveraging proprietary technologies.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
